JP2021523908A - 連鎖球菌毒素性ショック症候群 - Google Patents
連鎖球菌毒素性ショック症候群 Download PDFInfo
- Publication number
- JP2021523908A JP2021523908A JP2020564062A JP2020564062A JP2021523908A JP 2021523908 A JP2021523908 A JP 2021523908A JP 2020564062 A JP2020564062 A JP 2020564062A JP 2020564062 A JP2020564062 A JP 2020564062A JP 2021523908 A JP2021523908 A JP 2021523908A
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- protein
- streptococcal
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000650 Toxic shock syndrome Toxicity 0.000 title claims description 98
- 208000017757 Streptococcal toxic-shock syndrome Diseases 0.000 title claims description 95
- 206010044251 Toxic shock syndrome streptococcal Diseases 0.000 title claims description 95
- 239000012634 fragment Substances 0.000 claims abstract description 115
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 69
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 69
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims abstract description 58
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 54
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 51
- 230000027455 binding Effects 0.000 claims abstract description 18
- 230000003053 immunization Effects 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 80
- 201000010099 disease Diseases 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 231100000617 superantigen Toxicity 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 33
- 241000124008 Mammalia Species 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 108010010318 streptococcal M protein Proteins 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 17
- 101001066720 Rattus norvegicus Nuclear envelope pore membrane protein POM 121 Proteins 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 12
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 claims description 10
- 101710104359 F protein Proteins 0.000 claims description 10
- 230000036039 immunity Effects 0.000 claims description 9
- 238000002649 immunization Methods 0.000 claims description 8
- 231100000776 exotoxin Toxicity 0.000 claims description 6
- 239000002095 exotoxin Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000001568 sexual effect Effects 0.000 abstract description 2
- 230000035939 shock Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 200
- 210000002966 serum Anatomy 0.000 description 97
- 208000015181 infectious disease Diseases 0.000 description 63
- 230000001580 bacterial effect Effects 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- 231100000765 toxin Toxicity 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 43
- 239000003053 toxin Substances 0.000 description 43
- 108700012359 toxins Proteins 0.000 description 43
- 150000001413 amino acids Chemical group 0.000 description 41
- 230000035755 proliferation Effects 0.000 description 39
- 230000004044 response Effects 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 27
- 108090000695 Cytokines Proteins 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 210000004988 splenocyte Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 16
- 239000000499 gel Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 13
- 238000009169 immunotherapy Methods 0.000 description 13
- 238000006386 neutralization reaction Methods 0.000 description 13
- 206010040872 skin infection Diseases 0.000 description 13
- 206010061372 Streptococcal infection Diseases 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000003226 mitogen Substances 0.000 description 12
- 210000004989 spleen cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 238000001543 one-way ANOVA Methods 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 108091092584 GDNA Proteins 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 102000016607 Diphtheria Toxin Human genes 0.000 description 8
- 108010053187 Diphtheria Toxin Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229940027941 immunoglobulin g Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 229940037003 alum Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000011577 humanized mouse model Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 230000002297 mitogenic effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- -1 salt salt Chemical class 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 208000034486 Multi-organ failure Diseases 0.000 description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 108091006116 chimeric peptides Proteins 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 239000000304 virulence factor Substances 0.000 description 4
- 230000007923 virulence factor Effects 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 3
- 238000011238 DNA vaccination Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010034839 Pharyngitis streptococcal Diseases 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 208000006311 Pyoderma Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 101150084989 Speg gene Proteins 0.000 description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 238000011220 combination immunotherapy Methods 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 101150044687 crm gene Proteins 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000009331 sowing Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 101710154607 Azurocidin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical class [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010028885 Necrotising fasciitis Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010039587 Scarlet Fever Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001468181 Streptococcus sp. 'group C' Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000009176 antiserum therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000043635 human AZU1 Human genes 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 201000007970 necrotizing fasciitis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000007112 pro inflammatory response Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000009174 transverse myelitis Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MXYRZDAGKTVQIL-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methyloxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MXYRZDAGKTVQIL-IOSLPCCCSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- PXBWLHQLSCMJEM-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC2=C(O)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O PXBWLHQLSCMJEM-IOSLPCCCSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037637 Pyoderma streptococcal Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108700031314 Rotavirus VP6 Proteins 0.000 description 1
- 101150087119 SAG gene Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102100032741 SET-binding protein Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001415395 Spea Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010048960 Streptococcal sepsis Diseases 0.000 description 1
- 229940124840 Streptococcal vaccine Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002745 polystyrene-block- poly(ethylene /butylene) Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
好適には、上記側面によれば、前記哺乳動物はヒトである。
p145 LRRDLDA SREAKKQVEKAL E(配列番号1)
p*1. LRRDLDA ENEAKKQVEKAL E(配列番号13)
p*2. LRRDLDA EDEAKKQVEKAL E(配列番号14)
p*3. LRRDLDA EREAKNQVEKAL E(配列番号15)
p*4. LRRDLDA EREAKKQVERAL E(配列番号16)
p*5. LRRDLDA EREAKKQVEMAL E(配列番号17)
p*6. LRRDLDA VNEAKKQVEKAL E(配列番号18)
p*7. LRRDLDA VDEAKKQVEKAL E(配列番号19)
p*8. LRRDLDA VREAKNQVEKAL E(配列番号20)
p*9. LRRDLDA VREAKKQVERAL E(配列番号21)
p*10. LRRDLDA VREAKKQVEMAL E(配列番号22)
p*11. LRRDLDA SNEAKNQVEKAL E(配列番号23)
p*12. LRRDLDA SNEAKKQVERAL E(配列番号24)
p*13. LRRDLDA SNEAKKQVEMAL E(配列番号25)
p*14. LRRDLDA SDEAKNQVEKAL E(配列番号26)
p*15. LRRDLDA SDEAKKQVERAL E(配列番号27)
p*16. LRRDLDA SDEAKKQVEMAL E(配列番号28)
p*17 LRRDLDA SREAKNQVERAL E(配列番号6)
p*18. LRRDLDA SREAKNQVEMAL E(配列番号29)
本明細書で使用される場合、「J14ペプチド」は、アミノ酸配列KQAEDKVKASREAKKQVEKALEQLEDKVK(配列番号3)、その断片または多様体を含んでもよい。この配列は、p145内に最小のBおよびT細胞エピトープを有するペプチドである。このペプチドは、有害である可能性のあるT細胞自己エピトープを含まないが、オプソニン作用のあるB細胞エピトープを含むGASのMタンパク質C領域ペプチドであると特定された。J14は、Mタンパク質C領域(太字)の14アミノ酸を含み、ペプチドの正しいらせん折り畳みと立体構造を維持するのに必要な酵母由来のGCN4配列に隣接している、キメラペプチドである。
J8ペプチド多様体の非限定的な例としては、以下が挙げられる:
S R E A K K Q S R E A K K Q V E K A L K Q V E K A L C(配列番号7)
S R E A K K Q S R E A K K Q V E K A L K Q S R E A K C(配列番号8)
S R E A K K Q V E K A L K Q S R E A K K Q V E K A L C(配列番号9)
S R E A K K Q V E K A L D A S R E A K K Q V E K A L C (配列番号10)。
(材料および方法)
(結果)
(提案されたさらなる研究)
(要約)
(結果)
STSSのヒト化マウスモデルの確立
STSSのワクチン予防
STSSに対する免疫療法
SN1由来のMタンパク質は分裂促進効果を発揮し炎症誘発性応答に寄与する
(考察)
A群連鎖球菌emm89およびSpeCのISDとの関連は、最近の多くの報告、さらには日本(emm89がSTSS症例で2番目に優勢な遺伝子型であった)で指摘されている[35]。
Claims (25)
- 哺乳動物のA群連鎖球菌関連疾患、障害、または状態、好ましくは連鎖球菌毒素性ショック症候群(STSS)などの侵襲性A群連鎖球菌疾患(iGAS)に対する受動免疫付与、治療、または予防に使用するための、A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するか、それに対して産生された抗体または抗体断片、ならびに/あるいはA群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片。
- 哺乳動物のA群連鎖球菌関連疾患、障害、または状態、好ましくは連鎖球菌毒素性ショック症候群(STSS)などの侵襲性A群連鎖球菌疾患(iGAS)に対する免疫付与、治療、または予防に使用するための、A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体、ならびに/あるいはA群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体。
- 哺乳動物に連鎖球菌毒素性ショック症候群に対する受動免疫を付与する方法であって、前記哺乳動物にA群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片を投与することによって、前記哺乳動物の連鎖球菌毒素性ショック症候群に対する受動免疫を前記哺乳動物に付与する工程を含む、方法。
- A群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片を投与する工程をさらに含む、請求項3に記載の方法。
- 哺乳動物の連鎖球菌毒素性ショック症候群を治療または予防する方法であって、前記哺乳動物にA群連鎖球菌Mタンパク質、その断片、多様体、または誘導体、ならびに/あるいはA群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片を投与することによって、前記哺乳動物の連鎖球菌毒素性ショック症候群を治療または予防する工程を含む、方法。
- A群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体、ならびに/あるいはA群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片を投与する工程をさらに含む、請求項5に記載の方法。
- A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片を含む、哺乳動物への投与に適した組成物。
- A群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された抗体または抗体断片をさらに含む、請求項7に記載の組成物。
- A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体と、A群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体とを含む、哺乳動物への投与に適した組成物。
- 前記Mタンパク質断片は、前記Mタンパク質の保存領域であるかそれを含む、請求項1または2に記載の使用、請求項2〜6のいずれか一項に記載の方法、あるいは請求項7〜9のいずれか一項に記載の組成物。
- 前記Mタンパク質断片は、p145ペプチドであるか、それを含むか、それに含まれる、請求項10に記載の使用、方法、または組成物。
- 前記Mタンパク質断片は、J8ペプチド、その断片、多様体、または誘導体であるか、それを含むか、それに含まれる、請求項11に記載の使用、方法、または組成物。
- 前記Mタンパク質断片は、p17ペプチド、その断片、多様体、または誘導体であるか、それを含むか、それに含まれる、請求項11に記載の使用、方法、または組成物。
- 前記スーパー抗原は、連鎖球菌発熱性外毒素(Spe)AまたはSpeCである、請求項1〜13のいずれかに記載の使用、方法、または組成物。
- A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された前記抗体または抗体断片;ならびに/あるいはA群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された前記抗体または抗体断片は、モノクローナル抗体または抗体断片である、請求項1〜14のいずれかに記載の使用、方法、または組成物。
- A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された前記抗体または抗体断片;ならびに/あるいはA群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された前記抗体または抗体断片は、ヒト化モノクローナル抗体または抗体断片である、請求項1〜15のいずれかに記載の使用、方法、または組成物。
- 前記哺乳動物はヒトである、請求項1〜16のいずれかに記載の使用、方法、または組成物。
- A群連鎖球菌Mタンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生されたモノクローナル抗体またはその断片。
- A群連鎖球菌スーパー抗原タンパク質、その断片、多様体、または誘導体に結合するかそれに対して産生された、モノクローナル抗体またはその断片;あるいは抗体または抗体断片。
- 組み換え抗体または抗体断片である、請求項18または請求項19に記載のモノクローナル抗体またはその断片。
- ヒト化されている、請求項20に記載のモノクローナル抗体またはその断片。
- 請求項18〜21のいずれか一項に記載の組み換えモノクローナル抗体またはその断片をコードする単離核酸。
- 請求項22に記載の単離核酸を含む遺伝子構築物。
- 請求項23に記載の遺伝子構築物を含む宿主細胞。
- (i)請求項18〜21のいずれか一項に記載の抗体または抗体断片;(ii)請求項22に記載の単離核酸;(iii)請求項23に記載の遺伝子構築物;ならびに/あるいは(iv)請求項24に記載の宿主細胞を含む、組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018901709 | 2018-05-16 | ||
AU2018901709A AU2018901709A0 (en) | 2018-05-16 | Streptococcal toxic shock syndrome | |
AU2018904377A AU2018904377A0 (en) | 2018-11-16 | Streptococcal toxic shock syndrome | |
AU2018904377 | 2018-11-16 | ||
PCT/AU2019/050469 WO2019218022A1 (en) | 2018-05-16 | 2019-05-16 | Streptococcal toxic shock syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021523908A true JP2021523908A (ja) | 2021-09-09 |
JPWO2019218022A5 JPWO2019218022A5 (ja) | 2022-05-23 |
Family
ID=68539133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564062A Pending JP2021523908A (ja) | 2018-05-16 | 2019-05-16 | 連鎖球菌毒素性ショック症候群 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210292398A1 (ja) |
EP (1) | EP3806896A4 (ja) |
JP (1) | JP2021523908A (ja) |
KR (1) | KR20210010882A (ja) |
CN (1) | CN112449603A (ja) |
AU (1) | AU2019268417A1 (ja) |
BR (1) | BR112020023128A2 (ja) |
CA (1) | CA3100212A1 (ja) |
MX (1) | MX2020012245A (ja) |
SG (1) | SG11202011348YA (ja) |
WO (1) | WO2019218022A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240010712A1 (en) * | 2020-09-18 | 2024-01-11 | Tanea Medical Ab | Antibodies against streptococcal m protein |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505439A (ja) * | 1996-12-06 | 2001-04-24 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 変異体レンサ球菌毒素aおよび使用法 |
JP2002513278A (ja) * | 1996-12-06 | 2002-05-08 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 変異体レンサ球菌毒素cおよび使用法 |
US20090010929A1 (en) * | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
US20090162369A1 (en) * | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US20050010034A1 (en) * | 1997-12-05 | 2005-01-13 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin C and methods of use |
WO2002094851A2 (en) * | 2001-05-18 | 2002-11-28 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office | Peptide vaccines against group a streptococci |
-
2019
- 2019-05-16 SG SG11202011348YA patent/SG11202011348YA/en unknown
- 2019-05-16 US US17/055,294 patent/US20210292398A1/en active Pending
- 2019-05-16 AU AU2019268417A patent/AU2019268417A1/en active Pending
- 2019-05-16 BR BR112020023128-2A patent/BR112020023128A2/pt unknown
- 2019-05-16 CN CN201980047414.0A patent/CN112449603A/zh active Pending
- 2019-05-16 WO PCT/AU2019/050469 patent/WO2019218022A1/en active Application Filing
- 2019-05-16 CA CA3100212A patent/CA3100212A1/en active Pending
- 2019-05-16 MX MX2020012245A patent/MX2020012245A/es unknown
- 2019-05-16 KR KR1020207035598A patent/KR20210010882A/ko unknown
- 2019-05-16 JP JP2020564062A patent/JP2021523908A/ja active Pending
- 2019-05-16 EP EP19803402.7A patent/EP3806896A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505439A (ja) * | 1996-12-06 | 2001-04-24 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 変異体レンサ球菌毒素aおよび使用法 |
JP2002513278A (ja) * | 1996-12-06 | 2002-05-08 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 変異体レンサ球菌毒素cおよび使用法 |
US20090010929A1 (en) * | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
US20090162369A1 (en) * | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
Non-Patent Citations (2)
Title |
---|
CLINICAL INFECTIOUS DISEASES, 2006, VOL.43, PP.743-746, JPN6023018409, ISSN: 0005052472 * |
SCI. REP., 2015, 5:15825, JPN6023018410, ISSN: 0005052471 * |
Also Published As
Publication number | Publication date |
---|---|
EP3806896A1 (en) | 2021-04-21 |
BR112020023128A2 (pt) | 2021-02-02 |
EP3806896A4 (en) | 2022-06-29 |
CN112449603A (zh) | 2021-03-05 |
AU2019268417A1 (en) | 2020-12-03 |
CA3100212A1 (en) | 2019-11-21 |
MX2020012245A (es) | 2021-01-29 |
KR20210010882A (ko) | 2021-01-28 |
US20210292398A1 (en) | 2021-09-23 |
WO2019218022A1 (en) | 2019-11-21 |
SG11202011348YA (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7072921B2 (ja) | A群レンサ球菌ワクチン | |
KR100615109B1 (ko) | 모렉셀라 카타르할리스의 uspa1, uspa2 항원 | |
RU2757426C2 (ru) | Иммунногенный слитый белок | |
Yuan et al. | Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China | |
JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
Nagai et al. | Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection | |
JP2021523908A (ja) | 連鎖球菌毒素性ショック症候群 | |
JP2021000134A (ja) | 免疫低下状態の宿主のためのワクチン | |
JP2021505525A (ja) | A群レンサ球菌に対する免疫原性ペプチド | |
US20090162369A1 (en) | Synthetic chimeric peptides | |
US20030229454A1 (en) | Use of a computer to design a molecule | |
US20230190906A1 (en) | Non-toxic listeriolysin o polypeptides and uses thereof | |
US9913889B2 (en) | Immunogenic TP0751 fragments | |
WO2023227563A1 (en) | Protective staphylococcal exotoxin vaccine | |
JP2024512722A (ja) | 免疫原性融合タンパク質 | |
Ghosha et al. | An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development J | |
PANDEY et al. | Patent 2945052 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220513 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230809 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230829 |